Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2020

Open Access 01-12-2020 | Maintenance Therapy | Research article

Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study

Authors: Dai Koguchi, Kazumasa Matsumoto, Takahiro Hirayama, Shigetaka Moroo, Momoko Kobayashi, Hiroki Katsumata, Masaomi Ikeda, Masatsugu Iwamura

Published in: BMC Urology | Issue 1/2020

Login to get access

Abstract

Background

Data are scarce regarding intravesical maintenance therapy (MT) with the low-dose bacillus Calmette–Guérin (BCG) Tokyo strain. We investigated the efficacy and safety of MT with a half dose of the Tokyo strain for patients following transurethral resection of nonmuscle invasive bladder cancer (NMIBC).

Methods

This study retrospectively reviewed clinical data on 78 patients diagnosed with intermediate or high-risk NMIBC followed by either MT (n = 38) or IT alone (n = 40) between January 2012 and March 2018. Statistical analysis was performed to compare recurrence-free survival (RFS) and adverse effects between the two groups. BCG was instilled once weekly for 6 weeks as IT, then once weekly in 2-week for a total of 20 instillations over 3 years.

Results

Kaplan–Meier analyses showed that patients undergoing MT had significantly better RFS than did those undergoing IT alone (hazard ratio (HR):0.32, 95% confidence interval (CI):0.12–0.89, P = 0.02). The 3-year RFS was 65.0% in the IT group and 89.5% in the MT group. Multivariate analysis showed that MT was associated with a reduced risk of recurrence (HR: 0.32, 95% CI:0.11–0.93, P = 0.03). One MT patient (2.6%) exhibited progression.

Conclusions

The BCG Tokyo strain showed acceptable efficacy and safety in patients undergoing MT; thus, it is a potential treatment for preventing bladder cancer recurrence.
Literature
1.
Borkowska EM, Jedrzejczyk A, Marks P, Catto JWF, Kaluzewski B. EORTC risk tables – their usefulness in the assessment of recurrence and progression risk in nonmuscle-invasive bladder cancer in Polish patients. Cent Eur J Urol. 2013;66(1):14–20.CrossRef
2.
Walczak R, Bar K, Walczak J. The value of EORTC risk tables in evaluating recurrent non-muscle-invasive bladder cancer in everyday practice. Cent Eur J Urol. 2014;66(4):418–22.
3.
Quan Y, Jeong CW, Kwak C, Kim HH, Kim HS, Ku JH. Dose, duration and strain of Bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: meta-analysis of randomized clinical trials. Medicine. 2017;96(42):e8300.CrossRef
4.
Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer. 2016;2(1):27–36.CrossRef
5.
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.CrossRef
6.
7.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(10):1240–67.CrossRef
8.
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.CrossRef
9.
Wu C, Zhou X, Miao C, Zhang J, Tang Q, Chang X, et al. Assessing the feasibility of replacing standard-dose bacillus Calmette–Guérin immunotherapy with other intravesical instillation therapies in bladder cancer patients: a network meta-analysis. Cell Physiol Biochem. 2017;41(4):1298–312.CrossRef
10.
Zeng S, Yu X, Ma C, Zhang Z, Song R, Chen X, et al. Low-dose versus standard dose of Bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Medicine. 2015;94(49):e2176.CrossRef
11.
Wang Z, Xiao H, Wei G, Zhang N, Wei M, Chen Z, et al. Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model. BMC Cancer. 2018;18(1):1108.CrossRef
12.
Miyazaki J, Onozawa M, Takaoka E, Yano I. Bacillus Calmette–Guérin strain differences as the basis for immunotherapies against bladder cancer. Int J Urol. 2018;25(5):405–13.CrossRef
13.
Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette–Guérin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine. 2018;36(4):498–506.CrossRef
14.
Svatek RS, Tangen C, Delacroix S, Lowrance W, Lerner SP. Background and update for S1602 "a phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer. Eur Urol Focus. 2018;4(4):522–4.CrossRef
15.
Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette–Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer. 1995;75(2):552–9.CrossRef
16.
Kanagawa Urological Research Group (KURG). A 2-week maintenance regimen of intravesical instillation of Bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial. Jpn J Clin Oncol. 2012;42(9):813–9.
17.
Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose Bacillus Calmette–Guérin for superficial bladder cancer recurrence. Int J Urol. 2003;10(4):183–9.CrossRef
18.
Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, et al. Low-dose instillation therapy with Bacille Calmette–Guérin Tokyo 172 strain after transurethral resection: historical cohort study. Urology. 2008;71(6):1161–5.CrossRef
19.
Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect. J Urol. 2005;173(5):1507–12.CrossRef
20.
Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS. Efficacy of bacillus Calmette–Guérin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol. 2017;198(3):503–10.CrossRef
21.
Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T, Ogura K. A prospective comparative study of intravesical Bacillus Calmette–Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol. 2013;190(1):50–4.CrossRef
22.
Oddens JR, Brausi M, Sylvester RJ, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTCGU cancers group randomized study of maintenance Bacillus Calmette–Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–72.CrossRef
23.
van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R, et al. Intravesical instillation of epirubicin, Bacillus Calmette–Guérin and Bacillus Calmette–Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Uro. 2001;166(2):476–81.CrossRef
24.
Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, et al. Maintenance Therapy with 3-monthly Bacillus Calmette–Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol. 2015;68(2):256–62.CrossRef
25.
26.
27.
Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology. 2001;57(4):617–21.CrossRef
28.
de Reijke TM, Boer ECDE, Kurth KH, Schamhart DH. Urinary interleukin-2 monitoring during prolonged Bacillus Calmette– Guerin treatment: Can it predict the optimal number of instillations? J Urol. 1999;161(1):67–71.CrossRef
29.
Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, et al. Clinical impact of the increase in immunosuppressive cell-related gene expression in urine sediment during intravesical Bacillus Calmette–Guérin. Diseases. 2019;7(2):44.CrossRef
30.
Martínez-Piñeiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical Bacille Calmette–Guérin with a reduced dose of 27mg in superficial bladder cancer. BJU Int. 2002;89(7):671–80.CrossRef
31.
Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette–Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised Phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Assoc Urol. 2014;65(1):69–76.CrossRef
32.
Muto S, Nakajima A, Horiuchi A, Inoue M, China T, Saito K, et al. Maintenance therapy with intravesical bacillus Calmette–Guérin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer. Jpn J Clin Oncol. 2013;43(3):305–13.CrossRef
33.
Russell JS, Colevas AD. Adverse event monitoring in oncology clinical trials. Clin Invest. 2013;3(12):1157–65.CrossRef
Metadata
Title
Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study
Authors
Dai Koguchi
Kazumasa Matsumoto
Takahiro Hirayama
Shigetaka Moroo
Momoko Kobayashi
Hiroki Katsumata
Masaomi Ikeda
Masatsugu Iwamura
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00766-4

Other articles of this Issue 1/2020

BMC Urology 1/2020 Go to the issue

Research article

MicroRNA-219c-5p regulates bladder fibrosis by targeting FN1

Research article

Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome

Case report

The use of hyperbaric oxygen to treat actinic rectal fistula after SpaceOAR use and radiotherapy for prostate cancer: a case report

Case report

Burkitt’s lymphoma of the prostate presenting as acute urinary retention: a case report

Research article

Case series of glans injuries during voluntary medical male circumcision for HIV prevention — eastern and southern Africa, 2015–2018

Research article

Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands